J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia
J&J is adding a $230 million bonus deal to its $30 billion buyout of Actelion.
The pharma giant just snagged commercialization rights on aprocitentan (ACT-132577), which scored promising Phase II data for treatment resistant hypertension. Poised at the launch of a Phase III trial, J&J is handing over $160 million in cash and will follow up with a series of payments with the rest coming in installments over the next three and a half years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.